Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Vistagen reported significant improvement of physician- and patient-reported anxiety among trial participants who underwent an anxiety-inducing public speaking exercise.
First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years
Statistically significant rapid-onset reduction in patient-reported Subjective Units of.
Vistagen announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol nasal spray in adults diagnosed with social anxiety.
VistaGen Therapeutics (VTGN) Phase 3 PALISADE-2 Trial of Fasedienol Nasal Spray in Social Anxiety Disorder Meets Primary, Secondary Endpoints streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.